2025年11月29日,Eli Lilly、Novo Nordisk、AbbVie、Pfizer和Regeneron被强调为顶级药剂库存,原因是药效强劲和有希望的药品管道。 On Nov. 29, 2025, Eli Lilly, Novo Nordisk, AbbVie, Pfizer, and Regeneron were highlighted as top pharma stocks due to strong performance and promising drug pipelines.

2025年11月29日, 市场公司强调Eli Lilly、Novo Nordisk、AbbVie、Pfizer和Regeneron是最顶尖的药物储备, On November 29, 2025, MarketBeat highlighted Eli Lilly, Novo Nordisk, AbbVie, Pfizer, and Regeneron as top pharmaceutical stocks to watch, citing strong trading volume and progress in drug pipelines. 这些公司在治疗糖尿病、肥胖症、自发免疫疾病、癌症和罕见疾病方面起主导作用,其业绩受到监管决定、产品推出和市场需求的影响。 These companies lead in treating diabetes, obesity, autoimmune diseases, cancer, and rare conditions, with their performance influenced by regulatory decisions, product launches, and market demand. Eli Lilly和Novo Nordisk在糖尿病和肥胖治疗、AbbVie在自发免疫和肿瘤药物、Pfizer在传染病和疫苗、Regeneron在眼病治疗方面占有突出地位。 Eli Lilly and Novo Nordisk are prominent in diabetes and obesity therapies, AbbVie in autoimmune and oncology drugs, Pfizer in infectious diseases and vaccines, and Regeneron in eye disease treatments. 该部门仍然活跃,但面临波动和监管风险。 The sector remains dynamic but faces volatility and regulatory risks.